research BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.
Search
for
Sort by
Research
630-660 / 1000+ resultsresearch Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
Ritlecitinib is an effective new treatment for Alopecia Areata.
research Hair loss disorders (alopecias)
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
research Patched-assoziierte Tumoren: Modifikatorgene und Pathogenese
The document concludes that the development of certain tumors is influenced by genetic background and that a specific gene modification can lead to tumor regression and reduced growth.
research Epidermal Growth Factor Receptor Inhibitor–Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.
research A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
research Drug-Induced Alopecia Areata From Upadacitinib
Upadacitinib may cause hair loss.
research ES01.01 Chemotherapy is Strictly Additive to Immunotherapy
Chemotherapy adds to, but doesn't enhance, the effects of immunotherapy in lung cancer treatment.
research Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
research Deuruxolitinib for Alopecia Areata.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
research Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research Field Cancerization: From Molecular Basis to Selective Field-Directed Management of Actinic Keratosis
Photodynamic therapy is the preferred treatment for skin precancer due to its effectiveness and safety.
research 478 Mutation-specific siRNA Knockdown of GJB2 − Potential gene therapy for Keratitis-ichthyosis-deafness Syndrome
Targeted siRNA therapy may be a promising treatment for KID syndrome by reducing mutant gene expression and improving cell communication.
research JAK inhibitors in dermatology: The promise of a new drug class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Vandetanib
A man developed alopecia areata after starting cancer treatment with vandetanib.
research Pharmacophore Modeling and Three Dimensional Database Searching for Drug Design Using Catalyst: Recent Advances
The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
research Cyclosporine
Nonimmunosuppressive cyclosporines might treat skin diseases by affecting cell growth.
research JAK Inhibitors in Down Syndrome: Alopecia Areata Resolution and Vitiligo Improvement with Baricitinib
Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.
research A protein kinase target of a PDK1 signalling pathway is involved in root hair growth in Arabidopsis
AGC2-1 protein is essential for root hair growth in Arabidopsis.
research Jak inhibitors in the treatment of alopecia areata - a literature review
Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
research PAK4 signaling in health and disease: defining the PAK4–CREB axis
PAK4 is crucial in cancer progression, brain development, and could be a therapeutic target, especially through the PAK4-CREB axis.
research The Many Faces of Calcineurin Inhibitor Toxicity—What the FK?
Calcineurin inhibitors, used in kidney transplants, can cause a wide range of side effects including kidney damage and other health issues.
research Abstract P5-11-11: A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)
Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
research 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
research A new target for squamous cell skin cancer?
Prostaglandins and the enzyme AKR1C3 could play a role in skin cancer and hair loss, and further research is needed to understand these mechanisms.
research Incidence and management of cutaneous toxicities associated with cetuximab
Cetuximab often causes skin rashes, and managing these is important for cancer treatment.
research Aldesleukin
Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
research Tuning Scaffold Properties of New 1,4-Substituted Pyrrolo[3,2-c]quinoline Derivatives Endowed with Anticancer Potential, New Biological and In Silico Insights
Compound 7p shows strong potential as an anticancer agent.
research Multi-omics analysis unveils the role of cancer-associated fibroblasts in cutaneous squamous cell carcinoma
Cancer-associated fibroblasts promote tumor growth in skin cancer.